Trevi Therapeutics (NASDAQ:TRVI) Announces Quarterly Earnings Results

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01, Zacks reports.

Trevi Therapeutics Trading Down 2.1 %

NASDAQ TRVI traded down $0.14 during trading hours on Friday, reaching $6.47. 3,742,537 shares of the company's stock were exchanged, compared to its average volume of 991,462. The stock has a market cap of $497.32 million, a PE ratio of -14.70 and a beta of 0.90. Trevi Therapeutics has a one year low of $2.30 and a one year high of $7.39. The firm has a fifty day moving average of $4.60 and a 200-day moving average of $3.75.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their price target for the company from $9.00 to $29.00 in a report on Monday, March 10th. Needham & Company LLC cut their price target on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday. HC Wainwright reaffirmed a "buy" rating and issued a $12.50 price target on shares of Trevi Therapeutics in a report on Wednesday. Oppenheimer upped their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Seven investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $17.56.

Remove Ads

Insider Buying and Selling

In related news, insider Farrell Simon sold 81,313 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now directly owns 76,900 shares in the company, valued at $519,075. This represents a 51.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 24.37% of the stock is owned by corporate insiders.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.